UY37813A - Derivados de pirrolopiridina sustituidos - Google Patents

Derivados de pirrolopiridina sustituidos

Info

Publication number
UY37813A
UY37813A UY0001037813A UY37813A UY37813A UY 37813 A UY37813 A UY 37813A UY 0001037813 A UY0001037813 A UY 0001037813A UY 37813 A UY37813 A UY 37813A UY 37813 A UY37813 A UY 37813A
Authority
UY
Uruguay
Prior art keywords
disorders
atherosclerotic
substituted
pirrolopiridine
derivatives
Prior art date
Application number
UY0001037813A
Other languages
English (en)
Inventor
Olaf Panknin Dr
Kirstin Petersen Dra
Jeffrey Stuart Mowat Dr
Nuria Aiguabella Font Dra
Gabriele Leder Dra
Rafael Carretero Dr
Michael Meier Robin
Sandra Berndt Dra
Rienk Offringa
Roland Neuhaus Dr
Bernd Buchmann Dr
Original Assignee
Bayer Ag
Deutsches Krebsforsch
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Deutsches Krebsforsch, Bayer Pharma AG filed Critical Bayer Ag
Publication of UY37813A publication Critical patent/UY37813A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a derivados de pirrolopiridina sustituidos por inhibidores de proteína de la fórmula (I) a composiciones farmacéuticas y combinaciones que comprenden dichos compuestos, y a su uso profiláctico y terapéutico en trastornos neoplásicos, respectivamente cáncer o afecciones con respuestas inmunológicas desreguladas u otros trastornos asociados con la señalización de MAP4K1 aberrante, como único agente o en combinación con otros ingredientes activos, tales como hiperplasias benignas, trastornos ateroscleróticos, sepsis, trastornos autoinmunes, trastornos vasculares, infecciones virales, en trastornos neurodegenerativos, en trastornos inflamatorios, en trastornos ateroscleróticos y en el control de fertilidad masculina.
UY0001037813A 2017-07-18 2018-07-17 Derivados de pirrolopiridina sustituidos UY37813A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17181945 2017-07-18

Publications (1)

Publication Number Publication Date
UY37813A true UY37813A (es) 2019-02-28

Family

ID=59366337

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037813A UY37813A (es) 2017-07-18 2018-07-17 Derivados de pirrolopiridina sustituidos

Country Status (7)

Country Link
US (1) US11427578B1 (es)
EP (1) EP3655406A1 (es)
AR (1) AR112340A1 (es)
CA (1) CA3070013A1 (es)
TW (1) TW201908314A (es)
UY (1) UY37813A (es)
WO (1) WO2019016071A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020120257A1 (en) * 2018-12-11 2020-06-18 Bayer Aktiengesellschaft Substituted pyrrolopyridine-derivatives
WO2020255022A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
CN110483431A (zh) * 2019-09-04 2019-11-22 桂林南药股份有限公司 利奈唑胺杂质化合物、其制备方法以及其应用
CN110615790A (zh) * 2019-10-24 2019-12-27 北京融英医药科技有限公司 一种利格列汀制备工艺的改进方法
CN113354648A (zh) * 2020-03-03 2021-09-07 轶诺(浙江)药业有限公司 新型hpk1抑制剂及其制备方法和应用
WO2022253311A1 (zh) * 2021-06-04 2022-12-08 武汉人福创新药物研发中心有限公司 Hpk1抑制剂及其应用
EP4373817A1 (en) 2021-07-20 2024-05-29 Astrazeneca AB Substituted pyrazine-2-carboxamides as hpk1 inhibitors for the treatment of cancer
CN117003754A (zh) * 2022-04-28 2023-11-07 腾讯科技（深圳）有限公司 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
WO2001023389A2 (en) 1999-09-30 2001-04-05 Neurogen Corporation Certain alkylene diamine-substituted heterocycles
KR100768609B1 (ko) * 2003-07-09 2007-10-18 에프. 호프만-라 로슈 아게 티오페닐아미노이미다졸린
DE10357510A1 (de) 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
DE102004017438A1 (de) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2572331A1 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
US7470693B2 (en) 2005-04-21 2008-12-30 Bristol-Myers Squibb Company Oxalamide derivatives as kinase inhibitors
AU2006239632B2 (en) 2005-04-25 2012-03-15 Merck Patent Gmbh Novel AZA- heterocycles serving as kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1948185A4 (en) 2005-11-10 2010-04-21 Glaxosmithkline Llc INHIBITORS OF AKT ACTIVITY
WO2007103308A2 (en) 2006-03-07 2007-09-13 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
CN102086211B (zh) 2009-12-08 2013-09-11 广东东阳光药业有限公司 作为蛋白激酶抑制剂的芳杂环化合物
US9180127B2 (en) * 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
WO2012061290A2 (en) 2010-11-03 2012-05-10 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
EP2662372A1 (en) 2012-05-11 2013-11-13 Università Degli Studi Di Milano - Bicocca Alpha-carbolines for the treatment of cancer
EP3079683A4 (en) 2013-12-13 2017-12-20 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
AR101106A1 (es) 2014-07-02 2016-11-23 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
CA2989684A1 (en) 2015-06-25 2016-12-29 University Health Network Hpk1 inhibitors and methods of using same
CN110437145A (zh) 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用

Also Published As

Publication number Publication date
TW201908314A (zh) 2019-03-01
WO2019016071A1 (en) 2019-01-24
CA3070013A1 (en) 2019-01-24
EP3655406A1 (en) 2020-05-27
AR112340A1 (es) 2019-10-16
US11427578B1 (en) 2022-08-30

Similar Documents

Publication Publication Date Title
UY37813A (es) Derivados de pirrolopiridina sustituidos
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
DOP2019000117A (es) Nuevos derivados de quinolina
DOP2019000055A (es) Compuestos y composiciones como inhibidores de los receptores endosomales tipo peaje
CO2020001244A2 (es) Derivados de quinolina para tratar infecciones con helmintos
DOP2018000240A (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
ECSP15005376A (es) 2,3-benzodiacepinas
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
UY37789A (es) Nuevos derivados de azaquinolina
TN2015000354A1 (en) Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
UY37705A (es) Nuevos derivados de pirazol bicíclicos
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
UY37221A (es) Derivados de feniltriazol sustituidos con amida y usos de estos
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
UY37971A (es) Derivados de indol macrocíclicos sustituidos
BR112022008365A2 (pt) Inibidores de cd73
BR112016007462A2 (pt) fitonutrientes anti-inflamatórios para uso no tratamento ou prevenção de sinovite
BR112018000217A2 (pt) sistemas de distribuição de nanopartículas aperfeiçoados
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
ECSP20063701A (es) Formulación sólida de mezclas insecticidas
DOP2019000099A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos
CL2018002368A1 (es) Formulaciones de oritavancina
CO2021008962A2 (es) Derivados activos de éster de testosterona, composiciones y usos de los mismos
PH12018501804A1 (en) Dihydrochalcone derivatives influencing inflammatory states

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231110